慢性乙型肝炎患者口服拉米夫定耐药后HBV膜蛋白前S_2的变化  

Expression of the HBV Pre-S_2 protein on the lamivudine resistant in patients with chronic hepatitis B

作　　者：张妍[1] 刘小荣 

机构地区：[1]兰州市第二人民医院感染科,甘肃兰州730020 [2]甘肃省第二人民医院检验科,甘肃兰州730000

出　　处：《甘肃医药》2011年第6期336-337,共2页Gansu Medical Journal

摘　　要：目的:探讨150例慢性乙型肝炎患者口服拉米夫定一年产生耐药后HBV膜蛋白前S(2HBV-S2)的变化。方法:应用ELISA方法检测实验组(产生耐药)与对照组(未产生耐药)患者的血清HBV-S2。结果:对照组HBV-S2阳性48例(阳性率32%);实验组HBV-S2阳性117例(阳性率78%)。结论:产生耐药后HBV-S2的表达增加,表明耐药后HBV病毒又出现活动性复制,故检测HBV-S2的表达可及时指导临床医师调整治疗方案,避免延误病情及耐药菌株产生。Objective：To study the expression of HBV Pre-S2 protein（HBV Pre-S2）on the lamivudine resistant in patients with chronic hepatitis B after one-year oral administration of lamivudine.Methods： The expression of HBV Pre-S2 protein in experimental group（drug resistance group） and the control group（non-resistant group） was detected respectively by ELISA.Results： There was 48（32%） case of HBV-S2 positive patients in control group,and 117（78%） cases of HBV-S2 positive patients in experimental group.Conclusion： The expression of HBV-S2 increases after drug resistance,indicating that the virus has emerged active replication again after drug resistance in which the expression of HBV-S2 may guide the clinician to timely adjust treatment.

关 键 词：慢性乙型肝炎 耐药 拉米夫定 HBV膜蛋白前S2 

分 类 号：R512.62[医药卫生—内科学]